{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:29:13Z","timestamp":1792290553622,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T00:00:00Z","timestamp":1222905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s10549-008-0200-5","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T17:41:37Z","timestamp":1222882897000},"page":"595-602","source":"Crossref","is-referenced-by-count":102,"title":["Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer"],"prefix":"10.1007","volume":"116","author":[{"given":"James J.","family":"Dignam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Dukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P.","family":"Mamounas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Lawrence","family":"Wickerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,2]]},"reference":[{"key":"200_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.jncimonographs.a003460","volume":"30","author":"National Institutes of Health Consensus Development Panel","year":"2001","unstructured":"National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1\u20133, 2000. J Natl Cancer Inst Monogr 30:5\u201315","journal-title":"J Natl Cancer Inst Monogr"},{"key":"200_CR2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"200_CR3","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817\u20132826","journal-title":"N Engl J Med"},{"key":"200_CR4","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726\u20133734","journal-title":"J Clin Oncol"},{"key":"200_CR5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF01556838","volume":"1","author":"GF Robbins","year":"1977","unstructured":"Robbins GF, Berg J (1977) Curability of patients with invasive breast carcinoma based on a 30-year study. World J Surg 1:284\u2013286","journal-title":"World J Surg"},{"key":"200_CR6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/91.1.80","volume":"91","author":"T Karrison","year":"1999","unstructured":"Karrison T, Ferguson D, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80\u201385","journal-title":"J Natl Cancer Inst"},{"key":"200_CR7","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","volume":"14","author":"T Saphner","year":"1996","unstructured":"Saphner T, Tormey D, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738\u20132746","journal-title":"J Clin Oncol"},{"key":"200_CR8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1006133418245","volume":"52","author":"SG Hilsenbeck","year":"1998","unstructured":"Hilsenbeck SG, Ravdin PM, de Moor CA et al (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227\u2013237","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1022166517963","volume":"78","author":"K Hess","year":"2003","unstructured":"Hess K, Pusztai L, Buzdar A et al (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105\u2013118","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-006-9231-y","volume":"100","author":"WF Anderson","year":"2006","unstructured":"Anderson WF, Chen RE, Jatoi I et al (2006) Effect of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100:121\u2013126","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/jnci\/djh338","volume":"96","author":"B Fisher","year":"2004","unstructured":"Fisher B, Jeong J-H, Anderson S et al (2004) Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 96:1823\u20131831","journal-title":"J Natl Cancer Inst"},{"key":"200_CR12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(04)16981-X","volume":"364","author":"B Fisher","year":"2004","unstructured":"Fisher B, Jeong J-H, Bryant J et al (2004) Treatment of lymph node-negative, estrogen receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Lancet 364:858\u2013868","journal-title":"Lancet"},{"key":"200_CR13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM198902233200801","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Redmond C, Dimitrov NV et al (1989) A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473\u2013478","journal-title":"N Engl J Med"},{"key":"200_CR14","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1200\/JCO.1996.14.7.1982","volume":"14","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Mamounas EP et al (1996) Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14:1982\u20131992","journal-title":"J Clin Oncol"},{"key":"200_CR15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.2001.19.4.931","volume":"19","author":"B Fisher","year":"2001","unstructured":"Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931\u2013942","journal-title":"J Clin Oncol"},{"key":"200_CR16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 320:479\u2013484","journal-title":"N Engl J Med"},{"key":"200_CR17","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 88:1529\u20131542","journal-title":"J Natl Cancer Inst"},{"key":"200_CR18","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","volume":"89","author":"B Fisher","year":"1997","unstructured":"Fisher B, Dignam JJ, Wolmark N et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen-receptor positive breast cancer. J Natl Cancer Inst 89:1673\u20131682","journal-title":"J Natl Cancer Inst"},{"key":"200_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187\u2013220","journal-title":"J R Stat Soc B"},{"key":"200_CR20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","volume":"34","author":"RL Prentice","year":"1978","unstructured":"Prentice RL, Kalbfleisch JD, Peterson AV et al (1978) The analysis of failure times in the presence of competing risks. Biometrics 34:541\u2013554","journal-title":"Biometrics"},{"key":"200_CR21","volume-title":"The statistical analysis of failure time data","author":"J Kalbfleisch","year":"1980","unstructured":"Kalbfleisch J, Prentice R (1980) The statistical analysis of failure time data. Wiley, New York"},{"key":"200_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1009612117342","volume":"3","author":"D Sargent","year":"1997","unstructured":"Sargent D (1997) A flexible approach to time-varying coefficients in the Cox regression setting. Lifetime Data Anal 3:13\u201325","journal-title":"Lifetime Data Anal"},{"key":"200_CR23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1080\/01621459.1992.10476248","volume":"87","author":"RJ Gray","year":"1992","unstructured":"Gray RJ (1992) Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87:942\u2013951","journal-title":"J Am Stat Assoc"},{"key":"200_CR24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/sim.4780131007","volume":"13","author":"KR Hess","year":"1994","unstructured":"Hess KR (1994) Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 13:1045\u20131062","journal-title":"Stat Med"},{"key":"200_CR25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2307\/2533277","volume":"51","author":"PM Grambsch","year":"1995","unstructured":"Grambsch PM, Therneau TM, Fleming TR (1995) Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 51:1469\u20131482","journal-title":"Biometrics"},{"key":"200_CR26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2307\/2533197","volume":"50","author":"HG M\u00fcller","year":"1994","unstructured":"M\u00fcller HG, Wang JL (1994) Hazard rates estimation under random censoring with varying kernels and bandwidths. Biometrics 50:61\u201376","journal-title":"Biometrics"},{"key":"200_CR27","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/(SICI)1097-0258(19991130)18:22<3075::AID-SIM244>3.0.CO;2-6","volume":"18","author":"KR Hess","year":"1999","unstructured":"Hess KR, Serachitopol DM, Brown BW (1999) Hazard function estimators: a simulation study. Stat Med 18:3075\u20133088","journal-title":"Stat Med"},{"key":"200_CR28","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.295.14.1658","volume":"295","author":"DA Berry","year":"2006","unstructured":"Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658\u20131667","journal-title":"JAMA"},{"key":"200_CR29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2007.14.3222","volume":"26","author":"F Cardoso","year":"2008","unstructured":"Cardoso F, Van\u2019t Veer L, Rutgers E et al (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729\u2013735","journal-title":"J Clin Oncol"},{"key":"200_CR30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1006184428857","volume":"51","author":"J Bryant","year":"1998","unstructured":"Bryant J, Fisher B, G\u00fcnd\u00fcz N et al (1998) S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 51:239\u2013253","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR31","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262\u20131271","journal-title":"J Natl Cancer Inst"},{"key":"200_CR32","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2007.11.6798","volume":"26","author":"PE Goss","year":"2008","unstructured":"Goss PE, Ingle JN, Pater JL et al (2008) Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5\u00a0years of tamoxifen. J Clin Oncol 26:1948\u20131955","journal-title":"J Clin Oncol"},{"key":"200_CR33","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","volume":"26","author":"EP Mamounas","year":"2008","unstructured":"Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5\u00a0years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26:1965\u20131971","journal-title":"J Clin Oncol"},{"key":"200_CR34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2007.15.0946","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Winer EP (2008) Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26:798\u2013805","journal-title":"J Clin Oncol"},{"key":"200_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/ss\/998929473","volume":"16","author":"O Aalen","year":"2001","unstructured":"Aalen O, Gjessing H (2001) Understanding the shape of the hazard rate: a process point of view. Stat Sci 16:1\u201322","journal-title":"Stat Sci"},{"key":"200_CR36","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1198\/016214506000001068","volume":"101","author":"N Singpurwulla","year":"2006","unstructured":"Singpurwulla N (2006) The hazard potential: introduction and overview. J Am Stat Assoc 101:1705\u20131717","journal-title":"J Am Stat Assoc"},{"key":"200_CR37","volume-title":"Statistical models and methods for lifetime data","author":"J Lawless","year":"1982","unstructured":"Lawless J (1982) Statistical models and methods for lifetime data. Wiley, New York"},{"key":"200_CR38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijsu.2005.10.011","volume":"3","author":"D Berry","year":"2005","unstructured":"Berry D (2005) Breast cancer heterogeneity may explain peaks in recurrence. Int J Surg 3:287","journal-title":"Int J Surg"},{"key":"200_CR39","unstructured":"Dignam JJ, Dukic V (2008) Comment on: Yin W Di G, Zhou L et al. Time-varying patterns of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat Jun 21 (Epub ahead of print)"},{"key":"200_CR40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01807163","volume":"41","author":"R Demicheli","year":"1996","unstructured":"Demicheli R, Abbattista A, Miceli R et al (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41:177\u2013185","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1054\/bjoc.2001.1969","volume":"85","author":"R Demicheli","year":"2001","unstructured":"Demicheli R, Valagussa P, Bonadonna G (2001) Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer 85:490\u2013492","journal-title":"Br J Cancer"},{"key":"200_CR42","unstructured":"Baum M, Cuzick J, Howell A et al (2005) An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer. J Clin Oncol. 2005 ASCO annual meeting proceedings, vol 23, No. 16S (June 1 Supplement), p 612"},{"key":"200_CR43","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778\u2013785","journal-title":"J Clin Oncol"},{"key":"200_CR44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/sim.1349","volume":"22","author":"JH Jeong","year":"2003","unstructured":"Jeong JH, Jung SH, Wieand S (2003) A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med 22:339\u2013352","journal-title":"Stat Med"},{"key":"200_CR45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1214\/07-BA223","volume":"2","author":"V Dukic","year":"2007","unstructured":"Dukic V, Dignam J (2007) Bayesian hierarchical multiresolution model for the study of time-dependent patterns of failure in early stage breast cancer. Bayesian Anal 2:591\u2013610","journal-title":"Bayesian Anal"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0200-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0200-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0200-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:10:48Z","timestamp":1738404648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0200-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,2]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0200-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,2]]}}}